ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
64,559.69
-0.40%
S&P 500
5,473.17
-0.25%
Dow Jones
39,134.76
0.77%
US Dollar vs Yen
158.912
-0.01%
Brent Oil
84.975
-0.04%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Oramed Pharmaceuticals Inc (ORMP)

  7. Oramed Pharmaceuticals Inc (ORMP) ニュース

ORMP

Oramed Pharmaceuticals (ORMP)

Oramed Pharmaceuticals Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:ORMP
日付受信時刻ニュースソース見出しコード企業名
2024/06/2020 : 32Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ORMPOramed Pharmaceuticals Inc
2024/06/2020 : 30Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ORMPOramed Pharmaceuticals Inc
2024/06/1106 : 28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ORMPOramed Pharmaceuticals Inc
2024/06/1106 : 15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ORMPOramed Pharmaceuticals Inc
2024/05/1006 : 00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ORMPOramed Pharmaceuticals Inc
2024/05/0622 : 00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ORMPOramed Pharmaceuticals Inc
2024/03/1922 : 00GlobeNewswire Inc.Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and InnovationNASDAQ:ORMPOramed Pharmaceuticals Inc
2024/03/0707 : 00Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ORMPOramed Pharmaceuticals Inc
2024/02/2022 : 42Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ORMPOramed Pharmaceuticals Inc
2024/02/2022 : 30PR Newswire (US)Oramed Letter to ShareholdersNASDAQ:ORMPOramed Pharmaceuticals Inc
2024/01/3107 : 30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ORMPOramed Pharmaceuticals Inc
2024/01/2406 : 45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ORMPOramed Pharmaceuticals Inc
2024/01/2006 : 45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ORMPOramed Pharmaceuticals Inc
2024/01/0906 : 43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ORMPOramed Pharmaceuticals Inc
2024/01/0906 : 41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ORMPOramed Pharmaceuticals Inc
2024/01/0906 : 40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ORMPOramed Pharmaceuticals Inc
2024/01/0906 : 39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ORMPOramed Pharmaceuticals Inc
2024/01/0906 : 37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ORMPOramed Pharmaceuticals Inc
2024/01/0906 : 37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ORMPOramed Pharmaceuticals Inc
2024/01/0906 : 36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ORMPOramed Pharmaceuticals Inc
2024/01/0906 : 36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ORMPOramed Pharmaceuticals Inc
2024/01/0906 : 34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ORMPOramed Pharmaceuticals Inc
2024/01/0906 : 33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ORMPOramed Pharmaceuticals Inc
2024/01/0906 : 32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ORMPOramed Pharmaceuticals Inc
2024/01/0303 : 13Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ORMPOramed Pharmaceuticals Inc
2023/12/2123 : 26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ORMPOramed Pharmaceuticals Inc
2023/12/1906 : 45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ORMPOramed Pharmaceuticals Inc
2023/11/1007 : 10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ORMPOramed Pharmaceuticals Inc
2023/09/2705 : 34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ORMPOramed Pharmaceuticals Inc
2023/09/2300 : 38PR Newswire (US)Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding CompanyNASDAQ:ORMPOramed Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ORMP

最近閲覧した銘柄

USOTC
DBXVF
Xtrackers (GM)
BIT
UC6JX4
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有